Amrad halts buyback during Avexa spin-out
Thursday, 01 July, 2004
Amrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.
The process will allow the company to calculate the entitlements of shareholders so that shares can be distributed into the new company, Avexa, during the demerger. Amrad shareholders will receive shares in Avexa on a pro rata basis according to their holdings in Amrad on the record date for the offer.
The Amrad share buy-back program will continue once the record date has passed, the company said.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
